based on recent coy anncs and post on HC. Sign me up! I was...

based on recent coy anncs and post on HC. Sign me up! I was going to report the post for unsubstantiated ramping but decided to answer instead.

I prefer to look at the reality which Zero, Maldowl (whom the CEO won't take calls from), Grantjo and myself seem to be the only ones doing. Whoever criticised Zero needs only to look at the last few years' SP and FY reports, which reveal an ongoing fantastic salary + benefits for the CEO, a steeply increasing no. shares on issue due to CRs, a stagnant SP within a narrow range, and financials teetering on the edge of liquidation saved only by the aforementioned CRs and "shark" loans where more of this coy is given away by high interest or share issues. But we do have an enthusiastic chairman telling SHs the coy is in growth mode, so that's ok, he must know what he's doing.

Fall back to the old tried and true appeal to human greed by mentioning 10 -100 baggers and a re-structure to disguise more corporate uncertainty, and away we go again. The only 100 bagger I can recall, btw, was Poseidon Nickel in the 60's which was premised on a false projection of a mine's output quality, which brought about the introduction of the JORC code and its upgrades over the years, as I understand it. Hmmmm. Obviously I am not as knowledgeable as the CEO as she seems to refer to 100 baggers as being reasonably frequent, like we should all know about them. I bow to superior knowledge.

Midkine diagnostics have from memory pulled us in around $67K last FY from Pacific Edge, about the same as my corner fish&chip shop's takings. Sure sure, it's growing exponentially, so they tell us. Midkine therapeutics are a long way off commercialisation, Zoetis haven't come back to us, for example, as far as coy comms tell us, which are hazy at best imo.

Evolis has been marketed to the wrong demographic imo as I have stated repeatedly before, the product was reportedly short of stock in the distribution chain, the lids also reportedly failed in some instances, losing fluid and product the consumer just paid a premium price for, and now there seems to be no more marketing in Australia, not even shelf talkers! At least in the pharmacies I visit. IMO it is a cardinal failure to run short of stock during a marketing campaign, and the lids should not be failing, need I say more?

Will the US/Japan save us? I really don't know, but I really hope the QA and distribution lessons were learned here on homesoil before spreading our hairy largesse overseas. Only time will tell. And only bottom line dollars will give SHs a decent price uplift.

DYOR